The Bio Report

563 Episoder

1. Harnessing Biology to Address Global Challenges

   Udgivet: 29.10.2015
2. Immunotherapies ETF Lets Biotech Investors Bet on Emerging Sector

   Udgivet: 22.10.2015
3. Biotech Investors Turn Their Eyes to Policy Matters

   Udgivet: 16.10.2015
4. Why the MedTech Industry Should Worry About Future Innovation

   Udgivet: 8.10.2015
5. Rare Disease Drug Developer Shows Speed of Business Model

   Udgivet: 1.10.2015
6. Ensuring Value-Based Care Addresses What Matters to Patients

   Udgivet: 24.9.2015
7. California, Aid-in-Dying, and What We’ve Learned from Oregon

   Udgivet: 17.9.2015
8. FDA Guidance on Names for Biologics and Biosimilars and its Implications

   Udgivet: 10.9.2015
9. Understanding the Cost and Value of Cancer Therapies

   Udgivet: 3.9.2015
10. Jimmy Carter’s Final Wish: Eradicating Guinea Worm

    Udgivet: 27.8.2015
11. The Quest for a Pink Viagra

    Udgivet: 20.8.2015
12. Free Speech Ruling May Force FDA to Rethink Off-Label Marketing

    Udgivet: 14.8.2015
13. Drugmakers Often Late to Report Serious Side Effects

    Udgivet: 6.8.2015
14. When Hospital Cause, Rather than Cure, Deadly Infections

    Udgivet: 30.7.2015
15. Rethinking the Value and Price of Drugs

    Udgivet: 23.7.2015
16. Harnessing Stem Cells to Test Drug Safety

    Udgivet: 16.7.2015
17. CrowdMed Enlists the Wisdom of Crowds to Solve Medical Mysteries

    Udgivet: 9.7.2015
18. Biotech’s Record Performance and Looming Threats

    Udgivet: 2.7.2015
19. What a Decade of Investment Tells Us about the Health of Biotech

    Udgivet: 25.6.2015
20. What Activist Investors Can Teach Biotech Companies

    Udgivet: 18.6.2015